Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells.

Wang Y, Ngo VN, Marani M, Yang Y, Wright G, Staudt LM, Downward J.

Oncogene. 2010 Aug 19;29(33):4658-70. doi: 10.1038/onc.2010.218. Epub 2010 Jun 21.

PMID:
20562906
2.

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, Kelly G, Saunders B, Howell M, Downward J, Hancock DC.

Cell Res. 2012 Aug;22(8):1227-45. doi: 10.1038/cr.2012.82. Epub 2012 May 22.

3.

Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS.

Stelniec-Klotz I, Legewie S, Tchernitsa O, Witzel F, Klinger B, Sers C, Herzel H, Blüthgen N, Schäfer R.

Mol Syst Biol. 2012;8:601. doi: 10.1038/msb.2012.32.

4.

Adrenomedullin is a therapeutic target in colorectal cancer.

Wang L, Gala M, Yamamoto M, Pino MS, Kikuchi H, Shue DS, Shirasawa S, Austin TR, Lynch MP, Rueda BR, Zukerberg LR, Chung DC.

Int J Cancer. 2014 May 1;134(9):2041-50. doi: 10.1002/ijc.28542. Epub 2013 Nov 7.

5.

Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.

Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M.

Gut. 2009 Sep;58(9):1234-41. doi: 10.1136/gut.2008.159137. Epub 2009 May 26.

PMID:
19474002
6.

Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.

Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, Cleris L, Magistroni V, Formelli F, Gambacorti-Passerini CB.

Cancer Res. 2010 Sep 15;70(18):7253-63. doi: 10.1158/0008-5472.CAN-10-1108. Epub 2010 Sep 7.

7.

TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.

Luu C, Heinrich EL, Duldulao M, Arrington AK, Fakih M, Garcia-Aguilar J, Kim J.

PLoS One. 2013 Aug 1;8(8):e70604. doi: 10.1371/journal.pone.0070604. Print 2013.

8.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J.

BMC Med Genomics. 2010 Jun 30;3:26. doi: 10.1186/1755-8794-3-26.

9.

KRAS and YAP1 converge to regulate EMT and tumor survival.

Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, Zwang Y, Roberts TM, Root DE, Jacks T, Hahn WC.

Cell. 2014 Jul 3;158(1):171-84. doi: 10.1016/j.cell.2014.06.004. Epub 2014 Jun 19.

10.

Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium.

Keller JW, Franklin JL, Graves-Deal R, Friedman DB, Whitwell CW, Coffey RJ.

J Cell Physiol. 2007 Mar;210(3):740-9.

PMID:
17133351
11.

Interplay between oncogenic K-Ras and wild-type H-Ras in Caco2 cell transformation.

Ikonomou G, Kostourou V, Shirasawa S, Sasazuki T, Samiotaki M, Panayotou G.

J Proteomics. 2012 Sep 18;75(17):5356-69. doi: 10.1016/j.jprot.2012.06.038. Epub 2012 Jul 16.

PMID:
22800643
12.

RAS oncogenic signal upregulates EZH2 in pancreatic cancer.

Fujii S, Fukamachi K, Tsuda H, Ito K, Ito Y, Ochiai A.

Biochem Biophys Res Commun. 2012 Jan 20;417(3):1074-9. doi: 10.1016/j.bbrc.2011.12.099. Epub 2011 Dec 26.

PMID:
22222375
13.

Colorectal Carcinogenesis: Connecting K-RAS-Induced Transformation and CREB Activity In Vitro and In Vivo.

Steven A, Heiduk M, Recktenwald CV, Hiebl B, Wickenhauser C, Massa C, Seliger B.

Mol Cancer Res. 2015 Aug;13(8):1248-62. doi: 10.1158/1541-7786.MCR-14-0590. Epub 2015 May 1.

14.

Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells.

Hara T, Jones MF, Subramanian M, Li XL, Ou O, Zhu Y, Yang Y, Wakefield LM, Hussain SP, Gaedcke J, Ried T, Luo J, Caplen NJ, Lal A.

Oncotarget. 2014 Sep 15;5(17):7635-50.

15.

A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.

Bentley C, Jurinka SS, Kljavin NM, Vartanian S, Ramani SR, Gonzalez LC, Yu K, Modrusan Z, Du P, Bourgon R, Neve RM, Stokoe D.

Biochem J. 2013 Jun 1;452(2):313-20. doi: 10.1042/BJ20121578.

PMID:
23496764
16.

Activation of KRAS promotes the mesenchymal features of basal-type breast cancer.

Kim RK, Suh Y, Yoo KC, Cui YH, Kim H, Kim MJ, Gyu Kim I, Lee SJ.

Exp Mol Med. 2015 Jan 30;47:e137. doi: 10.1038/emm.2014.99.

17.

p120RasGAP is a mediator of rho pathway activation and tumorigenicity in the DLD1 colorectal cancer cell line.

Organ SL, Hai J, Radulovich N, Marshall CB, Leung L, Sasazuki T, Shirasawa S, Zhu CQ, Navab R, Ikura M, Tsao MS.

PLoS One. 2014 Jan 21;9(1):e86103. doi: 10.1371/journal.pone.0086103. eCollection 2014.

18.

Oncogenic RAS alters the global and gene-specific histone modification pattern during epithelial-mesenchymal transition in colorectal carcinoma cells.

Peláez IM, Kalogeropoulou M, Ferraro A, Voulgari A, Pankotai T, Boros I, Pintzas A.

Int J Biochem Cell Biol. 2010 Jun;42(6):911-20. doi: 10.1016/j.biocel.2010.01.024. Epub 2010 Jan 28.

PMID:
20109579
19.

Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.

Kikuchi H, Pino MS, Zeng M, Shirasawa S, Chung DC.

Cancer Res. 2009 Nov 1;69(21):8499-506. doi: 10.1158/0008-5472.CAN-09-2213. Epub 2009 Oct 20.

20.

KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines.

Yoshida Y, Tsunoda T, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Takashima Y, Sasazuki T, Kuroki M, Iwasaki A, Shirasawa S.

Anticancer Res. 2011 Jul;31(7):2535-9.

PMID:
21873171

Supplemental Content

Support Center